CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

So Jeong Lee, Cheong-Soo Hwang, Young-Keum Kim, Hyun Jung Lee, Sang-Jeong Ahn, Nari Shin, Jung Hee Lee, Dong Hoon Shin, Kyung Un Choi, Do Youn Park, Chang Hun Lee, Gi Young Huh, Mi Young Sol, Hee Jin Lee, Gyungyub Gong, Jee Yeon Kim, Ahrong Kim

Cancer Research and Treatment. 2017;49(2):313-321. Published online 2016 July 7 DOI: https://doi.org/10.4143/crt.2016.098

Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)–Positive Breast Cancers

Cancer Research and Treatment. 2017;49(2):313-321

Link1 Link2

Relevance of tumor infiltrating lymphocytes in patients with HER2 positive and triple negative breast cancer

C. Denkert

The Breast. 2017;32:S12

Link1 Link2

Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration

Shuzhen Liu, William D Foulkes, Samuel Leung, Dongxia Gao, Sherman Lau, Zuzana Kos, Torsten O Nielsen

Breast Cancer Research. 2014;16(5):

Link1

Link2

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

J.T. Thigpen

Yearbook of Oncology. 2012;2012:75-76

Link1 Link2

Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers

Kamaljeet Singh, Umadevi Tantravahi, Michele M. Lomme, Terese Pasquariello, Margaret Steinhoff, C. James Sung

Breast Cancer Research and Treatment. 2016;157(3):405-411

Link1

Link2

Human epidermal growth factor receptor 1 (EGFR) expression was not associated with gene amplification but intimately assoclated with HER2 gene amplification and protein expression in tissue microarray of clinical breast cancers

S.K. Ahn, Gwak, K. Park, J. Kim, H. Park, S. Han, S.K. Ahn

European Journal of Cancer Supplements. 2006;4(2):122-123

Link1 Link2

185 Management of Human Epidermal Growth Factor Receptor-2(HER2) Positive Breast Cancer Patients at University Hospitals of Leicester

M. Kaushik, T. Rattay, S. Shokuhi

European Journal of Cancer. 2012;48:S94

Link1 Link2

Managing metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in the older patient

Rachel A. Freedman, Hyman B. Muss

Journal of Geriatric Oncology. 2014;5(1):2-7

Link1 Link2

Human epidermal growth factor receptor 2 (HER2) extracellular domain levels are associated with progression-free survival in patients with HER2-positive metastatic breast cancer receiving lapatinib monotherapy

Allan Lipton, Kim Leitzel, Suhail M. Ali, Walter Carney, Greg Platek, Klaudia Steplewski, Ron Westlund, Robert Gagnon, Anne-Marie Martin, Julie Maltzman

Cancer. 2011;117(21):5013-5020

Link1

Tumor-infiltrating lymphocytes in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or the combination: a meta-analysis of published randomized clinical trials

The Breast. 2017;32:S105

Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.